Charles Schwab
CSTL icon

Charles Schwab’s Castle Biosciences CSTL Stock Holding History

Charles Schwab’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.94M Sell
241,880
-655
-0.3% -$21.5K ﹤0.01% 2333
2025
Q4 		$9.43M Buy
242,535
+4,381
+2% +$141K ﹤0.01% 2171
2025
Q3 		$5.42M Buy
238,154
+3,139
+1% +$63.8K ﹤0.01% 2402
2025
Q2 		$4.8M Sell
235,015
-7,243
-3% -$134K ﹤0.01% 2349
2025
Q1 		$4.85M Sell
242,258
-16,608
-6% -$411K ﹤0.01% 2284
2024
Q4 		$6.9M Sell
258,866
-15,895
-6% -$484K ﹤0.01% 2181
2024
Q3 		$7.84M Buy
274,761
+39,417
+17% +$1M ﹤0.01% 2156
2024
Q2 		$5.12M Buy
235,344
+30,407
+15% +$678K ﹤0.01% 2349
2024
Q1 		$4.54M Sell
204,937
-2,358
-1% -$51.3K ﹤0.01% 2325
2023
Q4 		$4.47M Buy
207,295
+6,306
+3% +$111K ﹤0.01% 2358
2023
Q3 		$3.39M Buy
200,989
+14,994
+8% +$262K ﹤0.01% 2424
2023
Q2 		$2.55M Buy
185,995
+2,329
+1% +$47.2K ﹤0.01% 2477
2023
Q1 		$4.17M Sell
183,666
-870
-0.5% -$21.3K ﹤0.01% 2287
2022
Q4 		$4.34M Buy
184,536
+6,910
+4% +$160K ﹤0.01% 2290
2022
Q3 		$4.63M Buy
177,626
+6,585
+4% +$185K ﹤0.01% 2250
2022
Q2 		$3.75M Buy
171,041
+4,928
+3% +$115K ﹤0.01% 2308
2022
Q1 		$7.45M Buy
166,113
+4,198
+3% +$173K ﹤0.01% 2094
2021
Q4 		$6.94M Buy
161,915
+3,492
+2% +$182K ﹤0.01% 2188
2021
Q3 		$10.5M Buy
158,423
+25,170
+19% +$1.77M ﹤0.01% 1978
2021
Q2 		$9.77M Buy
133,253
+16,606
+14% +$1.1M ﹤0.01% 2016
2021
Q1 		$7.99M Buy
116,647
+11,595
+11% +$871K ﹤0.01% 2073
2020
Q4 		$7.05M Buy
105,052
+19,526
+23% +$1.06M ﹤0.01% 2052
2020
Q3 		$4.4M Buy
85,526
+62,304
+268% +$2.77M ﹤0.01% 2126
2020
Q2 		$876K Buy
23,222
+620
+3% +$21.2K ﹤0.01% 2659
2020
Q1 		$674K Buy
22,602
+12,267
+119% +$370K ﹤0.01% 2604
2019
Q4 		$356K Buy
+10,335
New +$253K ﹤0.01% 2933

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab's CSTL Position: Q1 2026 in Review

Charles Schwab reduced its Castle Biosciences (CSTL) stake by 0.27% in Q1 2026, selling an estimated $21.5K and leaving 241,880 shares worth $5.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2333.

Charles Schwab first reported a position in CSTL in Q4 2019 and has held it in 26 quarters since. The position peaked at $10.5M in Q3 2021. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Charles Schwab held 241,880 shares of Castle Biosciences worth $5.94M as of Q1 2026.
  • Charles Schwab sold 655 Castle Biosciences shares in Q1 2026, an estimated $21.5K.
  • Castle Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #2333 holding.
  • Charles Schwab first reported a position in Castle Biosciences in Q4 2019 and has held it in 26 quarters since.
  • Charles Schwab's Castle Biosciences position peaked at $10.5M in Q3 2021.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.